Questions About Cancer? 1-800-4-CANCER

Adult Hodgkin Lymphoma Treatment (PDQ®)

Health Professional Version
Last Modified: 02/28/2014

Changes to This Summary (02/28/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Adult Hodgkin Lymphoma

Updated statistics with estimated new cases and deaths for 2014 (cited American Cancer Society as reference 1).

Stage Information for Adult Hodgkin Lymphoma

Revised text to state that positron emission tomography (PET) scans are usually combined with computed tomography (CT) scans for clinical staging. Also revised text to state that further prospective studies are needed to compare a PET response–adapted strategy versus standard therapy without alteration (cited Gallamini et al. as reference 8).

Added text to state that in a retrospective review of 454 patients, no patients with a positive bone marrow biopsy had only stage I or II disease on PET-CT scans; omission of the bone marrow biopsy for PET-CT–designated early-stage patients did not change treatment selection (cited El-Galaly et al. as reference 9).

Treatment Option Overview

Revised text to state that increasing exposure to alkylating agents in combined modality treatments or chemotherapy treatments alone may be a secondary cause of acute nonlymphocytic leukemia (cited Koontz et al. as reference 8).

Added Böll et al. as reference 61.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.